?These results are a monumental leap forward in pancreatic cancer treatment. The ESPAC-4 (European study group for pancreatic cancer) trial involved 732 patients from 92 hospitals in England, Scotland, Wales, Germany, France and Sweden. Cancer campaigners are hailing a ?monumental leap forward? in pancreatic cancer treatment after a new drug trial significantly extended survival from what is the most lethal form of the disease. ?This is one of the biggest ever breakthroughs prolonging survival for pancreatic cancer patients,? said Prof John Neoptolemos of Liverpool University, who lead the team of researchers. Meanwhile, separate research has also brought good news about lung cancer, which has the second worst survival rates among the commonest forms of cancer.